Cytokine | Brain trauma | Brain LPS | In vitro LPS |
---|---|---|---|
BLC | 5 | 4 | 2 |
Eotaxin | 5 | 4 | 2 |
GM-CSF | 5 | 4 | 2 |
IFNγ | 5 | 4 | 2 |
IL-1α | 4 | 4 | 3 |
IL-1β | 4 | 4 | 3 |
IL-2 | 4 | 4 | 3 |
IL-3 | 4 | 4 | 3 |
IL-4 | 4 | 4 | 3 |
IL-8 | 4 | 5 | 3 |
IL-9 | 4 | 5 | 3 |
IL-10 | 4 | 5 | 3 |
IL-12p40p70 | 4 | 5 | 3 |
IL-12p70 | 4 | 5 | 3 |
IL-13 | 5 | 5 | 3 |
IL-17 | 5 | 5 | 3 |
RANTES | 5 | 4 | 2 |
TIMP-1 | 5 | 4 | 2 |
TIMP-2 | 5 | 4 | 2 |
TNF-α | 3 | 4 | 3 |
sTNF RI | 3 | 4 | 3 |
sTNF RII | 3 | 4 | 3 |
Numbers indicate fold increase over respective −Dox groups. Results are the mean of two membranes for each treatment and condition. Unchanged cytokines are not shown (supplemental Fig. 2B, available at www.jneurosci.org as supplemental material). BLC, B-lymphocyte chemoattractant; GM-CSF, granulocyte macrophage colony stimulation factor; IfNγ, interferon-γ; IL, interleukin; RANTES, regulated on activation normal T-cell expressed and secreted; TIMP, tissue inhibitor of metalloproteinase; sTNF RI and RII, soluble TNF receptors I and II.